Screening platform for optimizing beneficial metabolite production in probiotic combinations
A proprietary bacterial screening approach to identify and optimize probiotic combinations that maximize production of beneficial metabolites such as short-chain fatty acids (SCFAs). Targets gut microbiome health by suppressing harmful bacteria growth through enhanced postbiotic output.
Overview
This solution focuses on characterizing and optimizing the production of beneficial metabolites, particularly short-chain fatty acids (SCFAs), generated by probiotic bacterial combinations. The underlying premise is that a healthy gut microbiome is defined by robust production of these metabolites, which simultaneously suppress the growth of undesirable bacteria. By systematically screening and combining probiotic strains, the approach aims to maximize the yield of these "good" metabolites in postbiotic formulations.
The offering is relevant for nutrition, supplement, and functional food companies seeking evidence-based probiotic formulations, as well as microbiome researchers and therapeutic developers interested in targeted gut health interventions. It addresses a growing market demand for scientifically validated probiotic products with demonstrable functional benefits.
Technical specifications
Key features:
- Proprietary screening methods to evaluate individual bacteria and combinations for metabolite production profiles
- Focus on short-chain fatty acids and other beneficial postbiotic metabolites
- Systematic optimization of bacterial consortia to maximize desired metabolite output
- Capability to assess suppressive effects on harmful bacterial growth
- Literature-informed baseline for identifying target metabolites associated with gut health
The approach leverages established knowledge of microbiome metabolite pathways combined with proprietary screening capabilities to identify high-performing probiotic combinations.
Technology readiness level
This research is at an early stage. The hypothesis is grounded in existing literature on gut microbiome metabolites, but no experimental validation has been performed to date. The next steps involve applying proprietary bacterial screening methods to evaluate various strain combinations and measure their metabolite production. Validation studies are planned to confirm which combinations optimize beneficial metabolite output. Organizations interested in co-development or sponsored research partnerships could accelerate the validation timeline.
About Spectral Platforms
Spectral Platforms is a biotechnology company focused on developing rapid diagnostic solutions for clinical microbiology. The company has created proprietary technology that detects bacterial pathogens by measuring metabolic markers and redox state changes in clinical samples. This approach aims to bypass traditional, time-consuming culture methods, offering diagnostic results for bacteria presence within 30 minutes. By enabling faster identification and antimicrobial susceptibility testing (AST), the platform is designed to provide actionable data for clinicians to initiate effective antibiotic therapy significantly earlier than current standards allow.
This technology is primarily intended for use in triaging patients at risk of sepsis and managing infectious diseases. By providing rapid and reliable results, including AST results for both single and poly-microbial samples, the company seeks to improve patient outcomes and optimize clinical decision-making. Founded in 2010 and based in Duarte, California, Spectral Platforms engages in research and development for the medical diagnostics industry, often working within the healthcare, biotechnology, and life sciences sectors to validate its diagnostic innovations for clinical environments.
delivered to your inbox.